Possible role of Resveratrol targeting Estradiol and Neprilysin pathways in Lipopolysaccharide model of Alzheimer disease

Advances in Experimental Medicine and Biology

Volumn 822, Issue , 2015, Pages 107-118

  El Sayed, Nesrine S ^a   Bayan, Yasmeen ^a  

^a GERMAN UNIVERSITY IN CAIRO   (Egypt)

Author keywords

Alzheimer disease; Estrogen; Lipopolysaccharide; Neprilysin; Resveratrol

Indexed keywords

AMYLOID BETA PROTEIN; ESTRADIOL; LIPOPOLYSACCHARIDE; MEMBRANE METALLOENDOPEPTIDASE; RESVERATROL; SODIUM CHLORIDE; ANTINEOPLASTIC AGENT; STILBENE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; HORMONAL REGULATION; LOCOMOTION; MAZE TEST; MEMORY DISORDER; MENTAL TEST; MOUSE; NONHUMAN; OPEN FIELD TEST; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RECOGNITION; TREATMENT DURATION; UPREGULATION; WORKING MEMORY; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; MEMORY; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DISEASE MODELS, ANIMAL; ESTRADIOL; LIPOPOLYSACCHARIDES; MEMORY; MICE; MOTOR ACTIVITY; NEPRILYSIN; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; STILBENES; TREATMENT OUTCOME;

EID: 84912017575     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-08927-0_12     Document Type: Article

References (59)

1. Arai K et al (2001) Deterioration of spatial learning performances in lipopolysaccharidetreated mice. Jpn J Pharmacol 87(3):195-201
2. Basly JP et al (2000) Estrogenic/antiestrogenic and scavenging properties of (E)-and (Z)-resveratrol. Life Sci 66(9):769-777
3. Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5(6):493-506
4. Brinton RD (2001) Cellular and molecular mechanisms of estrogen regulation of memory function and neuroprotection against Alzheimer’s disease: recent insights and remaining challenges. Learn Mem 8(3):121-133
5. Brookmeyer R et al (2011) National estimates of the prevalence of Alzheimer’s disease in the United States. Alzheimers Dement 7(1):61-73
6. Bowers JL et al (2000) Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141(10):3657-3667
7. Buxbaum JD et al (1992) Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc Natl Acad Sci U S A 89 (21):10075-10078
8. Canistro D et al (2009) Alteration of xenobiotic metabolizing enzymes by resveratrol in liver and lung of CD1 mice. Food Chem Toxicol 47(2):454-461
9. Chan V et al (2011) Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Curr Pharm Biotechnol 12(3):429-436
10. Collins MA et al (2009) Alcohol in moderation, cardioprotection, and neuroprotection: epidemiological considerations and mechanistic studies. Alcohol Clin Exp Res 33(2):206-219
11. Das DK, Maulik N (2006) Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol Interv 6(1):36-47
12. Doubek J et al. (2005) Effect of stilbene resveratrol on haematological indices of rats. Acta Vet Brno roč. 74, č. 2, s. 205-208. ISSN 0001-7213
13. Dubrovskaia NM et al (2009) Changes in the activity of amyloid-degrading metallopeptidases leads to disruption of memory in rats. Zh Vyssh Nerv Deiat Im I P Pavlova 59(5):630-638
14. El Sayed NS, Kassem LA, Heikal OA (2009) Promising therapy for Alzheimer’s disease targeting angiotensinconverting enzyme and the cyclooxygense-2 isoform. Drug Discov Ther 3(6):307-315
15. Hashimoto S et al (2010) Expression of neutral endopeptidase activity during clinical and experimental acute lung injury. Respir Res 11:164
16. Hauss-Wegrzyniak B, Wenk GL (2002) Beta-amyloid deposition in the brains of rats chronically infused with thiorphan or lipopolysaccharide: the role of ascorbic acid in the vehicle. Neurosci Lett 322(2):75-78
17. Heo S-K et al (2008) LPS induces inflammatory responses in human aortic vascular smooth muscle cells via Toll-like receptor 4 expression and nitric oxide production. Immunol Lett 120 (1-2):57-64
18. Howitz KT et al (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425(6954):191-196
19. Huang J et al (2005) Binding of estrogen receptor beta to estrogen response element in situ is independent of estradiol and impaired by its amino terminus. Mol Endocrinol 19 (11):2696-2712
20. Huang T-C et al (2011) Resveratrol protects rats from Aβ-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation. PLoS One 6(12):e29102
21. Huang J et al (2004) Estrogen regulates neprilysin activity in rat brain. Neurosci Lett 367 (1):85-87
22. Iwata N et al (2000) Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 6 (2):143-150
23. Iwata N et al (2002) Region-specific reduction of a beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J Neurosci Res 70(3):493-500
24. Iwuchukwu OF, Nagar S (2008) Resveratrol (trans-resveratrol, 3,5,40-trihydroxy-trans-stilbene) glucuronidation exhibits atypical enzyme kinetics in various protein sources. Drug Metab Dispos 36(2):322-330
25. Jacewicz M et al (2009) Systemic administration of lipopolysaccharide impairs glutathione redox state and object recognition in male mice. The effect of PARP-1 inhibitor. Folia Neuropathol 47(4):321-328
26. Jang M et al (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275(5297):218-220
27. Juan ME et al (2005) trans-Resveratrol, a natural antioxidant from grapes, increases sperm output in healthy rats. J Nutr 135(4):757-760
28. Karuppagounder SS et al (2009) Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer’s disease. Neurochem Int 54(2):111-118
29. Lanz T et al (1991) The role of cysteines in polyketide synthases. Site-directed mutagenesis of resveratrol and chalcone synthases, two key enzymes in different plant-specific pathways. J Biol Chem 266(15):99716
30. Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121-1159
31. Li F et al (2012) Resveratrol, a neuroprotective supplement for Alzheimer’s disease. Curr Pharm Des 18(1):27-33
32. Lublin AL, Gandy S (2010) Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer’s disease. Mt Sinai J Med 77(1):43-49
33. Madani R et al (2006) Lack of neprilysin suffices to generate murine amyloid-like deposits in the brain and behavioral deficit in vivo. J Neurosci Res 84(8):1871-1878
34. Marambaud P, Zhao H, Davies P (2005) Resveratrol promotes clearance of Alzheimer’s disease amyloid-beta peptides. J Biol Chem 280(45):37377-37382
35. Markus MA, Morris BJ (2008) Resveratrol in prevention and treatment of common clinical conditions of aging. Clin Interv Aging 3(2):331-339
36. Marr RA et al (2003) Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci 23(6):1992-1996
37. McGeer EG, McGeer PL (2001) Innate immunity in Alzheimer’s disease: a model for local inflammatory reactions. Mol Interv 1(1):22-29
38. Mokuno K et al (1994) Induction of manganese superoxide dismutase by cytokines and lipopolysaccharide in cultured mouse astrocytes. J Neurochem 63(2):612-616
39. Nasri S (2012) The effect of resveratrol flavonoid on learning and memory in passive avoidance and Y maze in diabetic rats. Adv Clin Exp Med 2012, 21(6), 705-711
40. Pervaiz S, Holme AL (2009) Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal 11(11):2851-2897
41. Picklo MJ et al (2002) Carbonyl toxicology and Alzheimer’s disease. Toxicol Appl Pharmacol 184(3):187-197
42. Pike CJ et al (2009) Protective actions of sex steroid hormones in Alzheimer’s disease. Front Neuroendocrinol 30(2):239-258
43. Ruitenberg A et al (2001) Prognosis of Alzheimer’s disease: the Rotterdam Study. Neuroepidemiology 20(3):188-195
44. Sahu SS et al. (2013) Neuroprotective effect of resveratrol against prenatal stress induced cognitive impairment and possible involvement of Atpase activity. Pharmacol Biochem Behav 103(3): 520-525
45. Selkoe DJ (2000) Imaging Alzheimer’s amyloid. Nat Biotechnol 18(8):823-824
46. Shaw KN, Commins S, O’Mara SM (2001) Lipopolysaccharide causes deficits in spatial learning in the watermaze but not in BDNF expression in the rat dentate gyrus. Behav Brain Res 124(1):47-54
47. Sheng JG et al (2003) Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol Dis 14(1):133-145
48. Simpkins JW, Wood BE, Balin BJ (2010) Alzheimer disease: the crisis is upon us. J Am Osteopath Assoc 110(9 Suppl 8):Sii-2
49. Soleas GJ, Diamandis EP, Goldberg DM (1997) Resveratrol: a molecule whose time has come? And gone? Clin Biochem 30(2):91-113
50. Sönmez U et al (2007) Neuroprotective effects of resveratrol against traumatic brain injury in immature rats. Neurosci Lett 420(2):133-137
51. Sparkman NL et al (2005) Peripheral lipopolysaccharide administration impairs two-way active avoidance conditioning in C57BL/6J mice. Physiol Behav 85(3):278-288
52. Suzuki T, Hata S (2009) [Progresses in the researches of Alzheimer’s disease to reveal the molecular mechanism of disease onset and establish the biochemical diagnostics at early stage]. Nihon Ronen Igakkai Zasshi 46(5):412-415
53. Swaab DF et al (2001) Structural and functional sex differences in the human hypothalamus. Horm Behav 40(2):93-98
54. Tang MX et al (1996) Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet 348(9025):429-432
55. Vegeto E et al (2001) Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia. J Neurosci 21(6):1809-1818
56. Wang H-W et al (2002) Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924(2):133-140
57. Williams EJ et al (2008) The effect of Escherichia coli lipopolysaccharide and tumour necrosis factor alpha on ovarian function. Am J Reprod Immunol 60(5):462-473
58. Wood JG et al (2004) Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430(7000):686-689
59. Xiao Z-M et al (2009) Estrogen regulation of the neprilysin gene through a hormoneresponsive element. J Mol Neurosci 39(1-2):22-26